المؤلفون: Mishra, Neha, Aden, Konrad, Blase, Johanna I, Baran, Nathan, Bordoni, Dora, Tran, Florian, Conrad, Claudio, Avalos, Diana, Jaeckel, Charlot, Scherer, Michael, Sørensen, Signe B, Overgaard, Silja H, Schulte, Berenice, Nikolaus, Susanna, Rey, Guillaume, Gasparoni, Gilles, Lyons, Paul A, Schultze, Joachim L, Walter, Jörn, Andersen, Vibeke, SYSCID Consortium, Dermitzakis, Emmanouil T, Schreiber, Stefan, Rosenstiel, Philip

المساهمون: Georges, Michel

المصدر: Genome Medicine, 14 (1), 110 (2022-09-24)

مصطلحات موضوعية: Biologics, Biomarker, Intestinal inflammation, Personalized medicine, Therapy response, Biomarkers, Tumor Necrosis Factor Inhibitors, Tumor Necrosis Factor-alpha, RNA, Interferons, Infliximab, Humans, Infliximab/therapeutic use, Interferons/therapeutic use, Prospective Studies, Inflammatory Bowel Diseases/drug therapy, Inflammatory Bowel Diseases/genetics, Inflammatory Bowel Diseases, Molecular Medicine, Molecular Biology, Genetics, Genetics (clinical), Life sciences, Genetics & genetic processes, Sciences du vivant, Génétique & processus génétiques

Relation: info:eu-repo/grantAgreement/EC/H2020/733100; https://link.springer.com/content/pdf/10.1186/s13073-022-01112-z.pdf; urn:issn:1756-994X

URL الوصول: https://orbi.uliege.be/handle/2268/302286

المؤلفون: Danese, Silvio, Colombel, Jean-Frederic, Lukas, Milan, Gisbert, Javier P, D'Haens, Geert, Hayee, Bu'hussain, Panaccione, Remo, Kim, Hyun-Soo, Reinisch, Walter, Tyrrell, Helen, Oh, Young S, Tole, Swati, Chai, Akiko, Chamberlain-James, Kirsten, Tang, Meina Tao, Schreiber, Stefan, GARDENIA Study

المساهمون: Louis, Edouard, Aboo, Nazimuddin, Ahmad, Tariq, Aldeguer Mante, Xavier, Allez, Matthieu, Almer, Sven, Altwegg, Romain, Andreu Garcia, Montserrat, Arasaradnam, Ramesh, Ardizzone, Sandro, Armuzzi, Alessandro, Arnott, Ian, Aumais, Guy, Avni-Biron, Irit, Barrow, Peter, Beales, Ian, Bermejo San Jose, Fernando, Bezuidenhout, Abraham, Biancone, Livia, Blaeker, Michael, Bloom, Stuart, Bokemeyer, Bernd, Bossa, Fabrizio, Bossuyt, Peter, Bouguen, Guillaume, Bouhnik, Yoram, Bouma, Gerd, Bourdages, Raymond, Bourreille, Arnaud, Boustiere, Christian, Brabec, Tomas, Brand, Stephan, Buening, Carsten, Buisson, Anthony, Cadiot, Guillaume, Calvet Calvo, Xavier, Carbonnel, Franck, Carpio, Daniel, Cheon, Jae Hee, Chiba, Naoki, Chioncel, Camelia, Cimpoeru, Nicoleta-Claudia, Clodi, Martin, Corazza, Gino Roberto, Cosintino, Rocco, Cotter, Jose, Creed, Thomas, Cummings, Fraser, Danese, Silvio, De' Angelis, Gian Luigi, De Maeyer, Marc, Desai, Milind, Desilets, Etienne, Desreumaux, Pierre, Dewit, Olivier, D'Haens, Geert, Dinter, Johanna, Dobru, Ecaterina Daniela, Douda, Tomas, Dumitrascu, Dan Lucian, Ebert, Matthias, Echarri Piudo, Ana, Elkhashab, Magdy, Eun, Chang Soo, Feagan, Brian, Fejes, Roland, Fidalgo, Catarina, Fishman, Sigal, Flourié, Bernard, Fowler, Sharyle, Fries, Walter, Fulop, Csaba, Fumery, Mathurin, G Kiss, Gyula, Gassner, Sonja, Gaya, Daniel, Germanà, Bastianello, Gheorghe, Liliana Simona, Gilletta de Saint Joseph, Cyrielle, Gionchetti, Paolo, Goldis, Adrian-Eugen, Gonçalves, Raquel, Grimaud, Jean-Charles, Gyökeres, Tibor, Hagege, Herve, Haidar, Andrei, Hartmann, Heinz, Hasselblatt, Peter, Hayee, Buhussain, Hebuterne, Xavier, Hellström, Per, Hindryckx, Pieter, Hlavova, Helena, Hoentjen, Frank, Howaldt, Stefanie, Hrdlicka, Ludek, Huh, Kyu Chan, Iborra Colomino, Maria Isabel, Ionita-Radu, Florentina, Irving, Peter, Jahnsen, Jørgen, Jang, ByungIk, Jansen, Jeroen, Jeon, Seong Woo, Jover Martinez, Rodrigo, Juillerat, Pascal, Karlén, Per, Kaser, Arthur, Keil, Radan, Kejariwal, Deepak, Keret, Dan, Khanna, Reena, Kim, Dongwoo, Kim, Duk Hwan, Kim, Hyo-Jong, Kim, Hyun-Soo, Kim, Joo Sung, Kim, Kueongok, Kim, Kyung-Jo, Kim, Sung Kook, Kim, Young-Ho, Klaus, Jochen, Kohn, Anna, Kojecky, Vladimir, Koo, Ja Seol, Kozak, Robert, Kremer, Milan, Kristof, Tunde, Kruger, Frederik, Laharie, David, Lahat-Zok, Adi, Landa, Evgeny, Lee, Jonghun, Lee, Kang-Moon, Lee, Kook Lae, Lee, YooJin, Lenze, Frank, Lim, Wee Chian, Limdi, Jimmy, Lindsay, James, Lopez Serrano, Pilar, Lueth, Stefan, Lukas, Milan, Maconi, Giovanni, Mana, Fazia, Mann, Steven, Mansfield, John, Marchi, Santino, Marino, Marco, Marshall, John, Martin Arranz, Maria Dolores, Mateescu, Radu-Bogdan, McLaughlin, John, McLaughlin, Simon, Melzer, Ehud, Mertens, Jessica, Mitrut, Paul, Molnar, Tamas, Muls, Vinciane, Munuswamy, Pushpakaran, Murray, Charles, Naftali, Timna, Naidoo, Visvakuren, Nanabhay, Yusuf, Negreanu, Lucian, Nguyen, Augustin, Ochsenkuehn, Thomas, Orlando, Ambrogio, Panaccione, Remo, Panes Diaz, Julian, Paritsky, Maya, Park, Dong Il, Park, Jihye, Pastorelli, Luca, Peck-Radosavljevic, Markus, Peerani, Farhad, Perez Gisbert, Javier, Peyrin-Biroulet, Laurent, Picon, Laurence, Pierik, Marieke, Ponich, Terry, Portela, Francisco, Prins, Maartens Jeroen, Racz, Istvan, Rahman, Khan Fareed, Reimund, Jean-Marie, Reinshagen, Max, Roblin, Xavier, Rocca, Rodolfo, Rogai, Francesca, Rogler, Gerhard, Salamon, Agnes, Salazar, Ennaliza, Sallo, Zoltan, Samuel, Sunil, Sans Cuffi, Miquel de Los Santos, Savarino, Edoardo Vincenzo, Savarino, Vincenzo, Savoye, Guillaume, Schreiber, Stefan, Seicean, Andrada, Selinger, Christian, Serra, David Martins, Shim, Hang Hock, Shin, SungJae, Siegmund, Britta, Siffledeen, Jesse, Simmonds, Wayne, Smid, Jan, Sollano, Jose, Song, Geun Am, Speight, Alexander, Sporea, Ioan, Staessen, Dirk, Stancu, George, Steel, Alan, Stepek, David, Stoica, Victor, Sturm, Andreas, Szekely, Gyorgy, Tan, Teck Kiang, Taxonera Samso, Carlos, Thomson, John, Tichy, Michal, Toth, Gabor Tamas, Tulassay, Zsolt, Vangeli, Marcello, Varga, Marta, Vieira, Ana, Viennot, Stephanie, Villa, Erica, Vitek, Petr, Vogelsang, Harald, Vyhnalek, Petr, Wahab, Peter, Walldorf, Jens, Ye, Byong Duk, Ziady, Christopher

المصدر: The Lancet Gastroenterology and Hepatology, 7 (2), 118-127 (2022-02)

مصطلحات موضوعية: Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, B72HH48FLU (Infliximab), I2A72G2V3J (etrolizumab), Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized/therapeutic use, Colitis, Ulcerative/drug therapy, Double-Blind Method, Female, Gastrointestinal Agents/therapeutic use, Humans, Infliximab/therapeutic use, Injections, Subcutaneous, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Young Adult, Human health sciences, Gastroenterology & hepatology, Sciences de la santé humaine, Gastroentérologie & hépatologie

Relation: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00294-6/fulltext; 10.1016/S2468-1253(21)00294-6; urn:issn:2468-1253

URL الوصول: https://orbi.uliege.be/handle/2268/304714

المؤلفون: Hafsah Nabi, Oliver Hendricks, Dorte Vendelbo Jensen, Anne Gitte Loft, Jens Kristian Pedersen, Søren Andreas Just, Kamilla Danebod, Heidi Lausten Munk, Salome Kristensen, Natalia Manilo, Ada Colic, Asta Linauskas, Pia Høger Thygesen, Louise Brot Christensen, Maren Høgberget Kalisz, Niels Lomborg, Stavros Chrysidis, Johnny Lillelund Raun, Marlene Andersen, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland, Bente Glintborg

المصدر: Nabi, H, Hendricks, O, Jensen, D V, Loft, A G, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Chrysidis, S, Raun, J L, Andersen, M, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2022, ' Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease : clinical outcomes in real-world patients from the DANBIO registry ', RMD Open, vol. 8, no. 2, e002560 . https://doi.org/10.1136/rmdopen-2022-002560
Nabi, H, Hetland, M L, Loft, A G, Hendricks, O, Jensen, D, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Grydehøj, J, Raun, J, Ahmed, R, Mehnert, F, Krogh, N S & Glintborg, B 2022, ' INFLIXIMAB BIOSIMILAR-TO-BIOSIMILAR SWITCHING IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: CLINICAL OUTCOMES IN REAL-WORLD PATIENTS FROM THE DANBIO REGISTRY ', Annals of the Rheumatic Diseases, vol. 81, no. Suppl. 1, OP0065, pp. 45-46 . https://doi.org/10.1136/annrheumdis-2022-eular.2306
Nabi, H, Hendricks, O, Jensen, D V, Loft, A G, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Chrysidis, S, Raun, J L, Andersen, M, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2022, ' Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease : Clinical outcomes in real-world patients from the DANBIO registry ', RMD Open, vol. 8, no. 2, 002560 . https://doi.org/10.1136/rmdopen-2022-002560
Nabi, H, Hendricks, O, Jensen, D V, Loft, A G, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Chrysidis, S, Raun, J L, Andersen, M, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2022, ' Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease : Clinical outcomes in real-world patients from the DANBIO registry ', RMD open, vol. 8, no. 2, 002560 . https://doi.org/10.1136/rmdopen-2022-002560

مصطلحات موضوعية: biosimilar pharmaceuticals, Arthritis, Psoriatic, Immunology, arthritis, rheumatoid, arthritis, psoriatic, Infliximab, Arthritis, Rheumatoid, Biosimilar Pharmaceuticals/therapeutic use, Infliximab/therapeutic use, Treatment Outcome, Rheumatology, Arthritis, Rheumatoid/diagnosis, Immunology and Allergy, Humans, Registries, spondylitis, ankylosing, infliximab, Biosimilar Pharmaceuticals, Arthritis, Psoriatic/diagnosis

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bcafac3b27cbee58119c12faba1e028
https://vbn.aau.dk/da/publications/1224b0b0-ee61-4f51-a117-2bb3d48fd527

المؤلفون: Peeters, H., Louis, Edouard, Baert, F., Dewit, O., Coche, J. C., Ferrante, M., Lambrecht, G., Colard, A., Van Gossum, A., Bossuyt, P., Moreels, T., Vander Cruyssen, B., Gils, A., De Vos, M.

المصدر: Acta Gastro-Enterologica Belgica, 81 (1), 15-21 (2018)

مصطلحات موضوعية: Adalimumab/therapeutic use, Adult, Aged, Belgium, Crohn Disease/drug therapy, Female, Gastrointestinal Agents/therapeutic use, Humans, Infliximab/therapeutic use, Male, Middle Aged, Prospective Studies, Treatment Outcome, Crohn's disease, adalimumab, infliximab, switching, Human health sciences, Gastroenterology & hepatology, Sciences de la santé humaine, Gastroentérologie & hépatologie

Relation: http://www.acta-gastroenterologica.be; urn:issn:1784-3227

URL الوصول: https://orbi.uliege.be/handle/2268/229798

المؤلفون: Manasi Agrawal, Francesca Petralia, Adam Tepler, Laura Durbin, Walter Reinisch, Jean-Frederic Colombel, Shailja C Shah

المصدر: Inflamm Bowel Dis
Agrawal, M, Petralia, F, Tepler, A, Durbin, L, Reinisch, W, Colombel, J-F & Shah, S C 2023, ' Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis : Individual Participant Data Meta-Analyses of Clinical Trials ', Inflammatory Bowel Diseases, vol. 29, no. 1, izac067, pp. 1-8 . https://doi.org/10.1093/ibd/izac067

مصطلحات موضوعية: Male, therapy, Remission Induction, Gastroenterology, individual participant data, meta-analysis, Infliximab/therapeutic use, Treatment Outcome, sex-based, Tumor Necrosis Factor Inhibitors/therapeutic use, Inflammatory Bowel Diseases/drug therapy, clinical trial data, gender, Humans, Immunology and Allergy, Female, Leading Off, tumor necrosis factor inhibitor, Colitis, Ulcerative/drug therapy, ulcerative colitis

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::898c75e41e6bbf118cc444671bf7d691
https://europepmc.org/articles/PMC10091488/

المؤلفون: Michael B MacIsaac, Richard B. Gearry, Alyson L Ross, Mette Julsgaard, Peter R. Gibson, Emma Flanagan, Sally Bell, Stephanie Rowe

المصدر: MacIsaac, M B, Julsgaard, M, Flanagan, E, Rowe, S, Ross, A L, Gearry, R B, Gibson, P R & Bell, S J 2022, ' Anti-TNFα Induction Therapy for Patients With Active Inflammatory Bowel Disease During Pregnancy : A Case Series ', Inflammatory Bowel Diseases, vol. 28, no. 4, pp. 652–655 . https://doi.org/10.1093/ibd/izab227

مصطلحات موضوعية: medicine.medical_specialty, Gastroenterology, Inflammatory bowel disease, Adalimumab/therapeutic use, Pregnancy, Internal medicine, Induction therapy, Inflammatory Bowel Diseases/drug therapy, medicine, Immunology and Allergy, Humans, Tumor Necrosis Factor-alpha/therapeutic use, Tumor Necrosis Factor-alpha, business.industry, Adalimumab, Induction Chemotherapy, Inflammatory Bowel Diseases, medicine.disease, Colitis, Infliximab, Infliximab/therapeutic use, Tumor necrosis factor alpha, Female, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4c17fc81b1537ba7bd9d6f3f027c4be
https://pure.au.dk/portal/da/publications/antitnf-induction-therapy-for-patients-with-active-inflammatory-bowel-disease-during-pregnancy(aa886956-5118-4df0-834c-a975b0d4a03d).html

المؤلفون: Benjamin A Fisher, Tonny Veenith, Daniel Slade, Charlotte Gaskell, Matthew Rowland, Tony Whitehouse, James Scriven, Dhruv Parekh, Madhu S Balasubramaniam, Graham Cooke, Nick Morley, Zoe Gabriel, Matthew P Wise, Joanna Porter, Helen McShane, Ling-Pei Ho, Philip N Newsome, Anna Rowe, Rowena Sharpe, David R Thickett, Julian Bion, Simon Gates, Duncan Richards, Pamela Kearns, Bryan Williams, Rebecca Turner, Vincenzo Libri, Francis Mussai, Gary Middleton, Sarah Bowden, Mansoor Bangash, Fang Gao-Smith, Jaimin Patel, Elizabeth Sapey, Mark Thomas, Mark Coles, Peter Watkinson, Naj Rahman, Brian Angus, Alexander J. Mentzer, Alex Novak, Marc Feldman, Alex Richter, Sian Faustini, Camilla Bathurst, Joseph Van de Wiel, Susie Mee, Karen James, Bushra Rahman, Karen Turner, Adam Hill, Anthony Gordon, Christina Yap, Michael Matthay, Danny McAuley, Andrew Hall, Paul Dark, Andrew McMichael

المساهمون: Investigators, CATALYST, National Institute for Health Research, UK Research and Innovation, NIHR

المصدر: investigators, CATALYST & Dark, P 2022, ' Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. ', The Lancet. Respiratory medicine, vol. 10, no. 3, pp. 255-266 . https://doi.org/10.1016/S2213-2600(21)00460-4
The Lancet. Respiratory Medicine

مصطلحات موضوعية: PNEUMONIA, Pulmonary and Respiratory Medicine, Adolescent, BLOCKADE, Respiratory System, Antibodies, Monoclonal, Humanized, COVID-19/drug therapy, 1117 Public Health and Health Services, Critical Care Medicine, General & Internal Medicine, Humans, TUMOR-NECROSIS-FACTOR, Science & Technology, SARS-CoV-2, COVID-19, CATALYST investigators, 1103 Clinical Sciences, Bayes Theorem, Standard of Care, Articles, COLONY-STIMULATING FACTOR, Infliximab, COVID-19 Drug Treatment, Infliximab/therapeutic use, Treatment Outcome, Life Sciences & Biomedicine, 1199 Other Medical and Health Sciences

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad54ed5704be7627c0e7cae395cc8c01
https://www.research.manchester.ac.uk/portal/en/publications/namilumab-or-infliximab-compared-with-standard-of-care-in-hospitalised-patients-with-covid19-catalyst-a-randomised-multicentre-multiarm-multistage-openlabel-adaptive-phase-2-proofofconcept-trial(df3f7821-b379-4211-8ca4-7e23572680d1).html

المؤلفون: Jan van den Brande, Tessa Uiterwaal, Christianne J. Buskens, Juda Vecht, Robert E G J M Pierik, Job H.C. Peters, Nofel Mahmmod, John Maring, E. Joline de Groof, Toer W. Stevens, H. B. A. C. Stockmann, Pieter C. F. Stokkers, Karlien F. Bruin, Eric J. Hazebroek, Ailsa Hart, Arnold van de Laar, Hubert A Prins, Richard van Hillegersberg, Rachel L. West, Paul Kingma, Menno A. Brink, Pritesh Morar, Ruud Schouten, Marno C.M. Rijk, A Jeroen de Groof, Sijbrand Hofker, Annekatrien Depla, Bregje Mol, Janneke van der Woude, T. J. Gardenbroek, Janindra Warusavitarne, Bas Oldenburg, Edwin S. van der Zaag, Anna A. W. van Geloven, Rogier M P H Crolla, Emma J. Eshuis, Hans Brouwer, Meindert N. Sosef, Maria L Haasnoot, Geert R. D'Haens, Nynke Talstra, Marcel Spanier, Liekele Oostenbrug, Jeroen M. Jansen, Maarten J Boom, Donald L. van der Peet, Nanne K. H. de Boer, Willem A. Bemelman, Cyriel Y. Ponsioen, Rosalie C Mallant, Theo J.M. van Ditzhuijsen, Gerard Dijkstra, Alexander P.J. Houdijk, Willem A. Marsman, Djuna Cahen, Casper G. Noomen, Huib A. Cense, Esther C. J. Consten, Michael F. Gerhards, Ad A. van Bodegraven, Rob J. Lieverse, Andreas Marinelli, Sjoerd van der Werff, Clemens Bolwerk, Ernst Jan Spillenaar Bilgen, Quirijn A. J. Eijsbouts, Guido Mannaerts, Bart A. van Wagensveld

المساهمون: ​Robotics and image-guided minimally-invasive surgery (ROBOTICS), Gastroenterology and hepatology, Surgery, AGEM - Digestive immunity, AII - Inflammatory diseases, Graduate School, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, Paediatric Surgery

المصدر: The lancet. Gastroenterology & hepatology, 5(10), 900-907. HANLEY & BELFUS-ELSEVIER INC
LIR!C study group 2020, ' Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease : retrospective long-term follow-up of the LIR!C trial ', The Lancet Gastroenterology and Hepatology, vol. 5, no. 10, pp. 900-907 . https://doi.org/10.1016/S2468-1253(20)30117-5
The Lancet Gastroenterology and Hepatology, 5(10), 900-907. Elsevier Ltd
lancet. Gastroenterology & hepatology, 5(10), 900-907. Elsevier Limited

مصطلحات موضوعية: Male, Cost-Benefit Analysis, Disease, Crohn Disease/etiology, law.invention, Laparoscopy/methods, 0302 clinical medicine, Crohn Disease, Quality of life, Randomized controlled trial, Adrenal Cortex Hormones, law, Cost-Benefit Analysis/methods, Cecum, Crohn's disease, Hazard ratio, Gastroenterology, Middle Aged, Immunologic Factors/therapeutic use, Treatment Outcome, 030220 oncology & carcinogenesis, Gastrointestinal Agents/therapeutic use, Female, 030211 gastroenterology & hepatology, medicine.drug, Adult, medicine.medical_specialty, Terminal Ileitis, Adrenal Cortex Hormones/therapeutic use, Cecum/pathology, 03 medical and health sciences, Gastrointestinal Agents, Ileum, medicine, Immunologic Factors, Humans, Retrospective Studies, Hepatology, Tumor Necrosis Factor-alpha, Tumor Necrosis Factor-alpha/antagonists & inhibitors, business.industry, Retrospective cohort study, medicine.disease, Ileum/pathology, Infliximab, Surgery, Infliximab/therapeutic use, Quality of Life, Laparoscopy, business, Follow-Up Studies

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e5752a7757a14a7ceff01b5b9c7a95a
https://doi.org/10.1016/s2468-1253(20)30117-5

المؤلفون: Jørn Brynskov, Nils Bolstad, Tobias Wirenfeldt Klausen, Casper Steenholdt, J. David Warren, Maria Dorn-Rasmussen, Jakob T Bay, Mark A. Ainsworth, Sine Buhl

المصدر: Dorn-Rasmussen, M, Buhl, S, Brynskov, J, Bay, J T, Bolstad, N, Klausen, T W, Warren, D J, Ainsworth, M A & Steenholdt, C 2022, ' Drug Levels Associated with Optimal Discrimination between Remission and Nonremission and Comparison of Antibody Assays during First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease ', Therapeutic Drug Monitoring, vol. 44, no. 2, pp. 290-300 . https://doi.org/10.1097/FTD.0000000000000913
Dorn-Rasmussen, M, Buhl, S, Brynskov, J, Bay, J T, Bolstad, N, Klausen, T W, Warren, D J, Ainsworth, M A & Steenholdt, C 2022, ' Drug Levels Associated with Optimal Discrimination Between Remission and Non-Remission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease ', Therapeutic Drug Monitoring, vol. 44, no. 2, pp. 290-300 . https://doi.org/10.1097/FTD.0000000000000913

مصطلحات موضوعية: medicine.medical_specialty, therapeutic drug monitoring, Inflammatory bowel disease, Gastroenterology, Antibodies, Maintenance therapy, Gastrointestinal Agents, inflammatory bowel disease, Internal medicine, Inflammatory Bowel Diseases/drug therapy, Dash, medicine, antibodies, Humans, Pharmacology (medical), antidrug antibodies, therapeutic thresholds, Retrospective Studies, Pharmacology, medicine.diagnostic_test, biology, business.industry, Retrospective cohort study, medicine.disease, Inflammatory Bowel Diseases, Infliximab, Infliximab/therapeutic use, Therapeutic drug monitoring, Immunoassay, biology.protein, Gastrointestinal Agents/therapeutic use, Antibody, Drug Monitoring, business, infliximab, medicine.drug

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b978e34369bfe6178bf230e4186c8b9
https://pubmed.ncbi.nlm.nih.gov/34387220

المؤلفون: Kennedy, Nicholas A, Goodhand, James R, Bewshea, Claire, Nice, Rachel, Chee, Desmond, Lin, Simeng, Chanchlani, Neil, Butterworth, Jeffrey, Cooney, Rachel, Croft, Nicholas M, Hart, Ailsa L, Irving, Peter M, Kok, Klaartje B, Lamb, Christopher A, Limdi, Jimmy K, Macdonald, Jonathan, McGovern, Dermot Pb, Mehta, Shameer J, Murray, Charles D, Patel, Kamal V, Pollok, Richard Cg, Raine, Timothy, Russell, Richard K, Selinger, Christian P, Smith, Philip J, Bowden, Jack, McDonald, Timothy J, Lees, Charlie W, Sebastian, Shaji, Powell, Nicholas, Ahmad, Tariq, Contributors To The CLARITY IBD Study

المساهمون: Imperial College Healthcare NHS Trust- BRC Funding, Kennedy, Nicholas A [0000-0003-4368-1961], Goodhand, James R [0000-0003-3112-376X], Bewshea, Claire [0000-0002-0965-9587], Chee, Desmond [0000-0003-3473-9447], Lin, Simeng [0000-0002-4201-4879], Chanchlani, Neil [0000-0003-0207-6706], Cooney, Rachel [0000-0003-3710-157X], Croft, Nicholas M [0000-0002-1519-6435], Hart, Ailsa L [0000-0002-7141-6076], Irving, Peter M [0000-0003-0972-8148], Kok, Klaartje B [0000-0002-5942-9149], Lamb, Christopher A [0000-0002-7271-4956], Limdi, Jimmy K [0000-0002-1039-6251], McGovern, Dermot Pb [0000-0001-5621-759X], Mehta, Shameer J [0000-0002-7002-293X], Murray, Charles D [0000-0001-6736-1546], Patel, Kamal V [0000-0003-2611-4260], Pollok, Richard Cg [0000-0001-6452-6763], Raine, Timothy [0000-0002-5855-9873], Russell, Richard K [0000-0001-7398-4926], Selinger, Christian P [0000-0003-2022-5859], Smith, Philip J [0000-0003-1568-3978], Bowden, Jack [0000-0003-2628-3304], McDonald, Timothy J [0000-0003-3559-6660], Lees, Charlie W [0000-0002-0732-8215], Sebastian, Shaji [0000-0002-3670-6545], Powell, Nicholas [0000-0003-3231-6950], Ahmad, Tariq [0000-0002-6058-5528], Apollo - University of Cambridge Repository

المصدر: 2021, ' Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab ', Gut, vol. 70, no. 5, pp. 865-875 . https://doi.org/10.1136/gutjnl-2021-324388
Gut

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Antibody Formation/immunology, Principal–agent problem, inflammatory diseases, autoimmune disease, Antibodies, Monoclonal, Humanized, Antibodies, Viral, SARS-CoV-2/immunology, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Gastrointestinal Agents, inflammatory bowel disease, Inflammatory Bowel Diseases/drug therapy, Economics, Humans, clarity, Serologic Tests, Antibodies, Viral/immunology, Prospective Studies, vedoluzimab, COVID-19/epidemiology, Poverty, Gastroenterology & Hepatology, SARS-CoV-2, United Kingdom/epidemiology, Gastroenterology, COVID-19, 1103 Clinical Sciences, Neoclassical economics, Middle Aged, Inflammatory Bowel Diseases, Bounded rationality, United Kingdom, Contributors to the CLARITY IBD study, Infliximab/therapeutic use, 030104 developmental biology, Antibodies, Monoclonal, Humanized/therapeutic use, Antibody Formation, Gastrointestinal Agents/therapeutic use, 1114 Paediatrics and Reproductive Medicine, 030211 gastroenterology & hepatology, Female, infliximab

وصف الملف: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document; text/xml

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b6e01dd054652cb9b8697520d2d594a
https://hdl.handle.net/20.500.11820/1bfd49d0-2ff9-4251-9b80-3c64409dface